What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Endocrinology
- Diabetes mellitus
His primary areas of investigation include Internal medicine, Endocrinology, Insulin, Glucagon-like peptide-1 and Glucagon.
His Type 2 diabetes research extends to Internal medicine, which is thematically connected.
His study involves Postprandial, Obesity, Weight loss, Glucose tolerance test and Insulin resistance, a branch of Endocrinology.
His studies in Postprandial integrate themes in fields like Ingestion, Ghrelin and Recurrent hypoglycemia.
The Insulin study combines topics in areas such as Diabetes mellitus and Bolus.
His study in Glucagon-like peptide-1 is interdisciplinary in nature, drawing from both Incretin, Small intestine, Gastrointestinal hormone, Enteroendocrine cell and Ileum.
His most cited work include:
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (1461 citations)
- A Randomized Trial Comparing a Very Low Carbohydrate Diet and a Calorie-Restricted Low Fat Diet on Body Weight and Cardiovascular Risk Factors in Healthy Women (687 citations)
- Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (639 citations)
What are the main themes of his work throughout his whole career to date?
David A. D'Alessio mostly deals with Internal medicine, Endocrinology, Insulin, Diabetes mellitus and Glucagon-like peptide-1.
His studies link Type 2 diabetes with Internal medicine.
Endocrinology is represented through his Glucagon, Incretin, Postprandial, Insulin resistance and Hormone research.
In his study, Saline is strongly linked to Ghrelin, which falls under the umbrella field of Insulin.
His Diabetes mellitus research incorporates elements of Body mass index, Gastric emptying and Surgery.
His work carried out in the field of Glucagon-like peptide-1 brings together such families of science as Gastrointestinal hormone, Receptor and Insulin secretion.
He most often published in these fields:
- Internal medicine (98.81%)
- Endocrinology (94.66%)
- Insulin (52.23%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (98.81%)
- Endocrinology (94.66%)
- Diabetes mellitus (32.94%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Endocrinology, Diabetes mellitus, Incretin and Receptor are his primary areas of study.
Many of his studies on Internal medicine involve topics that are commonly interrelated, such as Gastroenterology.
His is involved in several facets of Endocrinology study, as is seen by his studies on Glucagon, Islet, Carbohydrate metabolism, Postprandial and Insulin.
His studies deal with areas such as Meal and Gastric bypass surgery as well as Postprandial.
His Diabetes mellitus research includes elements of Obesity, Disease and Pharmacology.
The various areas that he examines in his Receptor study include Glucagon-like peptide-1, Proglucagon, Messenger RNA and Cell biology.
Between 2017 and 2021, his most popular works were:
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (1461 citations)
- Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (639 citations)
- Glucagon-like peptide 1 (GLP-1) (164 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Diabetes mellitus
- Endocrinology
David A. D'Alessio spends much of his time researching Diabetes mellitus, Internal medicine, Receptor, Endocrinology and Insulin.
His Diabetes mellitus study combines topics from a wide range of disciplines, such as Agonist, Sleeve gastrectomy and Obesity.
In his papers, David A. D'Alessio integrates diverse fields, such as Internal medicine and Placebo.
His Receptor research is multidisciplinary, incorporating perspectives in Incretin, Glucagon-like peptide-1, Pharmacology and Cell biology.
His Glucagon-like peptide-1 research is multidisciplinary, incorporating elements of Genetically modified mouse and Insulin resistance.
His work is connected to Hormone, Carbohydrate metabolism, Postprandial and Beta cell, as a part of Endocrinology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
